ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc

ANIP
Healthcare|Drug Manufacturers - Specialty & Generic|USA
$82.07
-1.68 (-2.01%)
DCF (FCF)
$45.65
Tangible Book
$1.43
Graham Number
$13.56

About

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Stock Price

+24.2%(1Y)

Pipeline Summary

15 total trials
0
Phase 1
2
Phase 2
4
Phase 3
6
Phase 4
Recruiting: 3Active: 3Completed: 5Terminated: 3Unknown: 1

Active Trials (6)

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
NCT07346079Gout Arthritis
Phase 4Recruiting
Enrollment: 150 participants
Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial
NCT07121634Cervical Ripening
N/AActive
Enrollment: 80 participants
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
NCT05322070Uveitis, Posterior
Phase 4Active
Enrollment: 125 participants
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
NCT06539481Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Phase 4Recruiting
Enrollment: 25 participants
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
NCT05486468Uveitis
Phase 3Recruiting
Enrollment: 30 participants

BioScore

4.5/10
Cautious

Ownership

Recent Insider Trades

CAREY STEPHEN P.SELL
2026-07-023,313 shares @ $86
CAREY STEPHEN P.SELL
2026-06-292,850 shares @ $84.12
Cook MeredithSELL
2026-06-12500 shares @ $82.03
HAUGHEY THOMASSELL
2026-06-082,000 shares @ $80.88
CAREY STEPHEN P.SELL
2026-06-053,312 shares @ $80

Recent News

2026-07-13 11:25:33
2026-07-10 13:06:44
2026-06-30 22:00:22
2026-06-16 00:01:18
Data last updated: Jul 13, 2026, 12:45 PM